Online inquiry

IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6670MR)

This product GTTS-WQ6670MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets MUC16 gene. The antibody can be applied in Ovarian Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001018016.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4582
UniProt ID P15941
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ6670MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11047MR IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MCLA-128
GTTS-WQ8464MR IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HTI-1088
GTTS-WQ12465MR IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA NKTR-214
GTTS-WQ568MR IVTScrip™ mRNA-Anti-G, 62-71-3(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 62-71-3
GTTS-WQ14631MR IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SC0001-SCX
GTTS-WQ7879MR IVTScrip™ mRNA-Anti-APCS, GSK-2398852(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GSK-2398852
GTTS-WQ10510MR IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY3002813
GTTS-WQ11720MR IVTScrip™ mRNA-Anti-IL13, MILR1444A(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MILR1444A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW